Recombinant human BAFFR / TNFRSF13C Protein, Fc Tag, 100 µg

Background
BAFF receptor (B-cell activating factor receptor, BAFF-R), also known as tumor necrosis factor receptor superfamily member 13C (TNFRSF13C), is a membrane protein of the TNF receptor superfamily which recognizes BAFF. B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells.

Source
Recombinant human BAFFR / TNFRSF13C, Fc Tag (BAR-H5257) is expressed from human 293 cells (HEK293). It contains AA Ser 7 - Ala 71 (Accession # Q96RJ3-1).
Predicted N-terminus: Ser 7

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 33.2 kDa. The protein migrates as 40-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.
 
Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Transcriptome Analysis of BAFF/BAFF-R System in Murine Nephrotoxic Serum Nephritis"
Möckel, Boegel, Schwarting
Int J Mol Sci (2024) 25 (10)
(2) "Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study"
Lu, Yin, Rao et al
BMC Cancer (2024) 24 (1), 439
(3) "IL-18-secreting multi-antigen targeting CAR T-cells eliminate antigen-low myeloma in an immunocompetent mouse model"
Ng, Rajagopalan, Kousa et al
Blood (2024)
Showing 1-3 of 577 papers.